MAFLD: What Is It?

Houston Methodist

D. Victor

Contrast Nephropathy

ARCH Advanced Revascularization Symposium

MetALD: What Is It, and How Do We Manage It?

Rush University Medical Center

L. Ritchie

Best Practices In Managing NAFLD / NASH

MedNews Week

D. Bernstein

New Horizons for Cardiorenal Protection: Q&A Panel Discussion

UT Health San Antonio School of Medicine

R. DeFronzo, K. R. Tuttle, E. Cersosimo, G. Bakris, C. Solis-Herrera, S. Bansal, A. Prasad

Pharmacologic Management of Alcohol Use Disorder

Scripps Health

R. Lee

Important Safety Information - Off-Target Effects of New Therapies f…

Ronald Goldenberg

The Fatty Liver Disease Epidemic

UPMC

M. Klinge

Sepsis and AKI - DAMPS & PAMPS

IRRIV International Renal Research Institute Vicenza

C. Ronco

Novel Biomarkers in Kidney Transplantation and Their Clinical Applic…

Houston Methodist

L. Riella

New Therapy for Fatty Liver Disease

Washington University in St. Louis

K. Korenblat

Using Resmetirom (THR-β Agonist) in Your Practice for MASH

Scripps Health

J. Gutierrez

Updates in Management for Patients with Cirrhosis

Duke Health

R. Doshi

Alcoholism is a Mid-brain Disease: Treat it as Such

Houston Methodist

H. Wetsman

Major Advancements in MASH Management

Rush University Medical Center

S. Janardhan

Alcohol Use Disorder (2024)

UCSF School of Medicine

T. Defries

Updates in Nephrology

University of Colorado Department of Medicine

A. Jovanovich

Effect of AV Access on Cardiovascular Systems

Insights From The World Congress of Nephrology 2024

L. Moist

Cutting Edge Diagnostics and Treatment for NAFLD

Northwestern Medicine Gastroenterology

M. E. Rinella, L. Van Wagner

Proton Pump Inhibitors: Debunking Media Myths

Houston Methodist

C. Kim